GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Accustem Sciences Inc (OTCPK:ACUT) » Definitions » Other Gross PPE

ACUT (Accustem Sciences) Other Gross PPE : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Accustem Sciences Other Gross PPE?

Accustem Sciences's Other Gross PPE for the quarter that ended in Dec. 2024 was $0.00 Mil.


Accustem Sciences Other Gross PPE Historical Data

The historical data trend for Accustem Sciences's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accustem Sciences Other Gross PPE Chart

Accustem Sciences Annual Data
Trend Dec22 Dec23 Dec24
Other Gross PPE
- - -

Accustem Sciences Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Accustem Sciences Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Accustem Sciences Business Description

Traded in Other Exchanges
N/A
Address
5 Penn Plaza, Suite 1954, Floor 19th, New York, NY, USA, 10001
Accustem Sciences Inc is a life sciences company that focuses on enhancing cancer patient outcomes through diagnostic, pharmaceutical, and medical device products. The company's product, StemPrintER, is a genomic platform for predicting distant recurrence risk in luminal, ER+/HER2-negative breast cancer patients. Additionally, It offers ancillary commodity testing to provide further insights. Validated in various retrospective cohorts, StemPrintER shows promise for oncology clinics. Revenue is generated through product commercialization and testing services. Operations span New York, NY, and London, UK.